title: [GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: literature review].
abstract: Uterine leiomyomas are the most frequent gynecological benign tumors. Their growth is regulated by ovarian steroids, therefore a hypoestrogenic state, like menopause or pharmacologically induced pseudo-menopause by GnRH-agonists or GnRH-antagonists, is associated with the decrease of their volume. This volume reduction allows a less invasive surgical procedure and may reduce the amount of blood loss during surgery. Therefore, GnRH-agonists and antagonists are used in presurgical treatment of uterine fibromatosis. This review analyses the effects of GnRH-agonists and GnRH-antagonists therapies. GnRH-agonists produce a down-regulation of GnRH receptor, while GnRH-antagonists compete with endogenous GnRH for pituitary binding sites. Due to the lack of any intrinsic activity of GnRH-antagonists, the characteristic initial flare-up observed with GnRH-agonist treatment is absent. So, GnRH-antagonists rapidly suppress gonadotropin release within 4-8 h, while GnRH-agonists show clinical effects after 2 or 3 weeks of treatment. GnRH-antagonist activity is dose-dependent so it is possible to adjust the dose to obtain the proper levels of inhibition. The GnRH-agonist presurgical treatment usually is a short-term therapy (3-6 months), because it causes side-effects like menopause symptoms. GnRH-antagonist clinical effects can be achieved with a short-time therapy too. Their side-effects include flushes and head-ache. After stopping therapy with both drugs, leiomyomas rapidly achieve their original size while side-effects disappear. Further studies are necessary to establish the use of GnRH-antagonists in leiomyomas therapy, but in Italy this is not possible because their use is not approved.
authors.affiliation: Dipartimento di Scienze Ostetrico-Ginecologiche e Urologiche e Medicina della Riproduzione Università Federico II di Napoli, Napoli, Italy.
authors.forename: M
authors.initials: M
authors.lastname: De Falco
authors.forename: F
authors.initials: F
authors.lastname: Pollio
authors.forename: M
authors.initials: M
authors.lastname: Pontillo
authors.forename: E
authors.initials: E
authors.lastname: Ambrosino
authors.forename: A
authors.initials: A
authors.lastname: Busiello
authors.forename: I F
authors.initials: IF
authors.lastname: Carbone
authors.forename: F
authors.initials: F
authors.lastname: Ciociola
authors.forename: M A
authors.initials: MA
authors.lastname: Di Nardo
authors.forename: L
authors.initials: L
authors.lastname: Landi
authors.forename: A
authors.initials: A
authors.lastname: Di Lieto
mesh_terms: D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000601:surgery; D011300:Preoperative Care; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D007987:Gonadotropin-Releasing Hormone